Liz Down
Graduate Research Assistant
E.A.Down@exeter.ac.uk
Smeall building
Smeall Building, University of Exeter, St Luke's Campus, Heavitree Road, Exeter, EX1 2LU, UK
Overview
Liz is part of the DISCO team, which focusses on cancer diagnostics. She is currently working on a project using routine records from primary care to investigate patient ethnicity and differences in blood test results, and the impact of these differences on diagnosis of common cancers.
Liz has previously worked as Data Manager for the IDEAL-2 study, a cohort study of the determinants of ‘living well’ with dementia, and as Data Manager on the CAP and ProtecT studies of prostate cancer care at the University of Bristol.
She has also worked in clinical audit at the Royal Devon & Exeter hospital, focusing on myocardial ischaemia (MINAP) and heart failure.
Publications
Journal articles
Down E, Barlow M, Bailey S, Mounce L, Martins T (In Press). Association between patient ethnicity and prostate cancer diagnosis following a Prostate Specific Antigen test: a cohort study of 730,000 men in primary care in the UK. BMC Medicine
Down E, Barlow M, Bailey S, Mounce L, Martins T (In Press). Association between patient ethnicity and prostate cancer diagnosis following a Prostate Specific Antigen test: a cohort study of 730,000 men in primary care in the UK. BMC Medicine
Barlow M, Down L, Mounce LTA, Merriel SWD, Watson J, Martins T, Bailey SER (2023). Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review. Prostate Cancer Prostatic Dis, 26(2), 249-256. Abstract. Author URL.
Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI, Lane JA, Noble S, Oliver SE, Evans S, et al (2018). Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. JAMA, 319(9), 883-883. Abstract.
Lane JA, Er V, Avery KNL, Horwood J, Cantwell M, Caro GP, Crozier A, Smith GD, Donovan JL, Down L, et al (2018). ProDiet: a Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. Cancer Prev Res (Phila), 11(11), 687-696. Abstract. Author URL.
Johnston TJ, Shaw GL, Lamb AD, Parashar D, Greenberg D, Xiong T, Edwards AL, Gnanapragasam V, Holding P, Herbert P, et al (2017). Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. Eur Urol, 71(3), 381-388. Abstract. Author URL.
Walsh EI, Turner EL, Lane JA, Donovan JL, Neal DE, Hamdy FC, Martin RM, the CAP & ProtecT Trial Groups, Investigators, Research staff, et al (2016). Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. Trials, 17(1). Abstract. Author URL.
Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JAC, Lane JA, I Walsh E, Hill EM, Down L, Ben-Shlomo Y, et al (2016). Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: is reliance on death certification good enough? a comparison with blinded review by an independent cause of death evaluation committee. Br J Cancer, 115(1), 90-94. Abstract. Author URL.
Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KNL, Dedman D, Down L, Mason MD, Neal DE, et al (2016). Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU International, 118(6), 869-879. Abstract.
Thorn JC, Turner EL, Hounsome L, Walsh E, Down L, Verne J, Donovan JL, Neal DE, Hamdy FC, Martin RM, et al (2016). Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). BMJ Open, 6(4). Abstract. Author URL.
Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL, Mason MD, Metcalfe C, Peters TJ, et al (2014). Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol, 15(10), 1109-1118. Abstract. Author URL.
Turner EL, Metcalfe C, Donovan JL, Noble S, Sterne JAC, Lane JA, Avery KN, Down L, Walsh E, Davis M, et al (2014). Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). Br J Cancer, 110(12), 2829-2836. Abstract. Author URL.
Thorn JC, Turner E, Hounsome L, Walsh E, Down L, Donovan J, Verne J, Neal D, Hamdy F, Martin RM, et al (2014). Validation of the Hospital Episode Statistics Outpatient Dataset in England. Value Health, 17(7), A547-A548. Author URL.
Lane JA, Davis M, Down E, Macefield R, Neal D, Hamdy F, Donovan J, Taylor H (2013). Evaluation of source data verification in a multicentre cancer trial (PROTECT). Trials, 14(Suppl 1), O80-O80.
Avery KNL, Donovan JL, Gilbert R, Davis M, Emmett P, Down L, Oliver S, Neal DE, Hamdy FC, Lane JA, et al (2013). Men with prostate cancer make positive dietary changes following diagnosis and treatment. Cancer Causes Control, 24(6), 1119-1128. Abstract. Author URL.
Oxley JD, Corbishley C, Down L, Watkin N, Dickerson D, Wong NACS (2012). Clinicopathological and molecular study of penile melanoma. J Clin Pathol, 65(3), 228-231. Abstract. Author URL.
Lane JA, Wade J, Down L, Bonnington S, Holding PN, Lennon T, Jones AJ, Salter CE, Neal DE, Hamdy FC, et al (2011). A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. J Clin Epidemiol, 64(6), 628-636. Abstract. Author URL.
Murad AS, Down L, Davey Smith G, Donovan JL, Athene Lane J, Hamdy FC, Neal DE, Martin RM (2011). Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer, 128(6), 1442-1448. Abstract. Author URL.
Down L, Metcalfe C, Martin RM, Neal DE, Hamdy FC, Donovan JL, Lane JA (2011). Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. BJU Int, 108(9), 1409-1414. Abstract. Author URL.
Lane AJ, Down L, Wade J, Neal D, Hamdy F, Donovan J (2011). Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial. Trials, 12(S1).
Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KNL, Blazeby JM, Down L, Neal DE, Hamdy FC, Vedhara K, et al (2010). Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer, 102(9), 1335-1340. Abstract. Author URL.
Macefield RC, Lane JA, Metcalfe C, Down L, Neal DE, Hamdy FC, Donovan JL (2009). Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?. Eur J Cancer, 45(14), 2569-2573. Abstract. Author URL.
Down L, Metcalfe C, Avery K, Noble S, Lane JA, Neal DE, Hamdy FC, Donovan JL (2009). Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. J Clin Epidemiol, 62(1), 67-73. Abstract. Author URL.
Turner EL, Lane JA, Metcalfe C, Down L, Donovan JL, Hamdy F, Neal D, Vedhara K (2009). Psychological distress and prostate specific antigen levels in men with and without prostate cancer. Brain Behav Immun, 23(8), 1073-1078. Abstract. Author URL.
Lane JA, Howson J, Donovan JL, Goepel JR, Dedman DJ, Down L, Turner EL, Neal DE, Hamdy FC (2007). Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. BMJ, 335(7630). Abstract. Author URL.
